Market Overview

BioDelivery Sciences Investors Have Been Burned, But Inflection Point Could Be Coming

BioDelivery Sciences Investors Have Been Burned, But Inflection Point Could Be Coming
Related BDSI
Earnings Scheduled For March 17, 2017
15 Biggest Mid-Day Losers For Tuesday
Matinas BioPharma Has A Weak Drug Pipeline And Investors With Fraudulent Histories - Expect A Big Decline (Seeking Alpha)
  • The share price of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) has increased 15.01 percent over the last five trading days.
  • Roth Capital’s Scott R. Henry has maintained a Buy rating on the company, with a price target of $14.
  • Henry believes that an inflection point could be imminent, following the recent signing of a two-year contract with Tennessee Medicaid, which makes Bunavail the preferred treatment for opioid dependence.

Analyst Scott Henry explained that “Bunavail (buprenorphine/naloxone) is a buccal film for the treatment of opioid addiction. It has potential benefits over comparable treatments, including a lower rate of constipation side effects.”

Tennessee is the largest Medicaid state for buprenorphine/naloxone treatment of opioid dependence. The recently signed contract between Tennessee Medicaid and BioDelivery Sciences came into effect on October 1, making Bunavail “the only preferred buprenorphine/ naloxone treatment for opioid dependence on the preferred drug list.”

See Also: Endo Pharmaceuticals, BioDelivery Sciences Present Promising Data On New Chronic Pain Management Product

With regard to the weekly data on the drug’s performance, the number of total prescriptions fell to 1,415 in the week of September 28, as compared to 1,477 total prescriptions for the previous week.

Bunavail’s market share declined marginally from 1.01 percent in the week of September 21 to 0.97 percent in the week of September 28. However, Henry views the weekly results as neutral, given the “currently modest expectations.”

The drug is expected to garner one percent market share by January 2016, increasing to 2 percent by November 2016.

Latest Ratings for BDSI

Sep 2016Janney CapitalUpgradesNeutralBuy
May 2016Cantor FitzgeraldDowngradesBuyHold
Mar 2016Roth CapitalMaintainsBuy

View More Analyst Ratings for BDSI
View the Latest Analyst Ratings

Posted-In: Roth Capital Scott R. HenryAnalyst Color Health Care Reiteration Analyst Ratings General Best of Benzinga


Related Articles (BDSI)

View Comments and Join the Discussion!